Format

Send to:

Choose Destination
See comment in PubMed Commons below
Cancer Epidemiol Biomarkers Prev. 1994 Mar;3(2):177-82.

5-Alpha-reductase inhibition and prostate cancer prevention.

Author information

  • 1Division of Cancer Prevention and Control, National Cancer Institute, Bethesda, Maryland 20892.

Abstract

Studies of prostate biology support the concept that dihydrotestosterone is the principal androgen responsible for normal and hyperplastic growth of the prostate gland. Cancer is a process of malignant transformation evolving over time, involving cellular growth and division. Therefore, an altered endocrine state, such as suppression of dihydrotestosterone activity, may have an impact on prostate cells inhibiting carcinogenic transformation. In vitro and in vivo preclinical observations support this hypothesis. A placebo-controlled randomized trial using finasteride, an inhibitor of the enzyme that converts testosterone to dihydrotestosterone, is planned. The endpoint of this trial will be reduction of prostate cancer incidence.

PMID:
8049641
[PubMed - indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire
    Loading ...
    Write to the Help Desk